Science 37 | Tufts Center for the Study of Drug Development, TUFTS UNIVERSITY

# Science 37's Direct-to-Patient Site vs. Industry Benchmarks

| | Science 37 DTP Site (FDA INSPECTED) | Industry Benchmark | Impact |
|---|---|---|---|
| **Enrollment Contribution**<br>Avg. participants enrolled per site / trial | **~150**<br>**patients per trial**<br>**(20–30% of total study enrollment)** | ~26<br>patients per site<br>(in traditional sites) | 6x MORE |
| **Trial Completion Rate**<br>% of enrolled completing the trial | **86.3 %**<br>**of enrolled patients completed the trial** | 35.7%<br>of enrolled patients completed the trial | >50% HIGHER |
| **Timeline Performance**<br>First Patient First Visit → Database Lock | **693 days**<br>**avg. FPFV to DBL**<br>**12.5% under planned timeline** | 814 days<br>avg. FPFV to DBL<br>~1% over planned timeline | 121 days FASTER |
| **Patient Representation**<br>Key demographics | Women: 62.4% DTP, 49% Benchmark<br>White: 59.3% DTP, 81.3% Benchmark<br>Black: 19.9% DTP, 7% Benchmark<br>*(lower = more diverse)* | | 3x MORE BLACK PATIENTS |

*Source: Tufts CSDD & Science 37, 2026. Benchmark = traditional sites with no DCT solutions (Tufts CSDD 2022/2025 datasets).*

## About the Data

Science 37 and Tufts CSDD published the first peer-reviewed study comparing a direct-to-patient (DTP) site's performance against established industry benchmarks. Science 37 contributed its DTP study data and Tufts CSDD provided benchmark datasets and methodology.

## Science 37 DTP Site Sample

**28** **Studies**

- Phases I, II, III, IV, & Observational
- All major therapeutic areas
- Orphan & non-orphan indications (32% orphan)

## Tufts CSDD Benchmark

**76** **Studies across 857 traditional sites**

- Phases II, III
- Trials with zero DCT solutions

Science 37 | Tufts Center for the Study of Drug Development, TUFTS UNIVERSITY

# Science 37's Direct-to-Patient Site Delivers Shorter Timelines

**74 days**
**saved**
**FPFV → LPFV**

**121 days**
**saved**
**FPFV → Database Lock**

**12.5%**
**ahead of plan**
**FPFV → Database Lock**

## Average Cycle Times (Days)




> When added alongside traditional sites, Science 37 meaningfully improves study performance.

Read the Peer-Reviewed Analysis

Disclaimer: The information presented reflects Science 37's experience and observations across studies utilizing its direct-to-patient clinical trial model. Certain performance metrics referenced herein are based on a retrospective analysis conducted jointly by Science 37 and the Tufts Center for the Study of Drug Development (Tufts CSDD) and should not be interpreted as guarantees of future performance or outcomes. Individual study results may vary significantly based on protocol design, therapeutic area, patient population, sponsor requirements, operational considerations, and other factors.



## Get in Touch with Our Team

Send an email to sales@science37.com
or visit www.science37.com

Science 37 — One Site. Any Patient. Total Access.